Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative and Oncology Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EphA4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EphA4 ECD-Fc Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View EphA4 Products |
| Gene Delivery | EphA4 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional assay validation. |
View EphA4 Products |
| Benchmark Ab | Anti-EphA4 Benchmark Antibody Recombinant monoclonal positive control for binding and neutralization assays. |
View EphA4 Products |
| Validator | EphA4 siRNA Set Target-specific knockdown verification in cell-based functional assays. |
View EphA4 Products |
| Related Target A | EFNA1 (Ephrin-A1) Primary high-affinity ligand for EphA4; crucial for competitive binding and activation studies. |
View EFNA1 Products |
| Related Target B | EFNB3 (Ephrin-B3) Cross-subfamily ligand that binds EphA4; essential for selectivity and off-target profile screening. |
View EFNB3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation (Cyno/Mouse) | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity by SDS-PAGE. |
| Subfamily off-target counter screening | Homolog panel proteins (EphA1-EphA8) strictly verified by mass spectrometry and sequence analysis. |
| Lack of reliable positive controls | Clinical-grade benchmark antibodies (biosimilars) included for assay standardization. |
| False positives in phenotype screens | Sequence-verified siRNA included for target-specific knockdown validation. |
Live EphA4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EphA4 therapeutics is intensifying, with major players shifting focus from traditional mAbs to blood-brain barrier (BBB)-penetrant small molecules, bispecific antibodies, and decoy receptor formats. As first-generation therapies reach the clinic, the next wave of R&D is targeting neurodegenerative indications like Amyotrophic Lateral Sclerosis (ALS) and spinal cord injury, alongside selective oncology indications where EphA4 drives tumor progression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies / Decoy Receptors | Academic Institutes, Biotech Startups | ALS, Spinal Cord Injury, Stroke | Ligand-blocking assays (Need high-purity ECD-Fc and ligand proteins like EFNA1/EFNB3) |
| Bispecific Antibodies (e.g., TfR shuttles) | CNS-focused Biopharma | Alzheimer's Disease, Neurodegeneration | Dual-targeting validation (Need cross-reactive proteins and stable cell lines) |
| Small Molecule Inhibitors | Oncology & Neurology Biotechs | Solid Tumors (Glioma), ALS | Selectivity profiling (Need Eph family kinase panels and Lentivirus for cellular assays) |